Literature DB >> 8374369

Hepatitis B vaccination: protection for how long and against what?

A J Hall.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8374369      PMCID： PMC1678572          DOI： 10.1136/bmj.307.6899.276

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  8 in total

1.  Hepatitis B vaccination: how long does protection last?

Authors:  W Jilg; M Schmidt; F Deinhardt; R Zachoval
Journal:  Lancet       Date:  1984-08-25       Impact factor: 79.321

2.  Vaccination against hepatitis B and protection against chronic viral carriage in The Gambia.

Authors:  H C Whittle; H Inskip; A J Hall; M Mendy; R Downes; S Hoare
Journal:  Lancet       Date:  1991-03-30       Impact factor: 79.321

3.  Efficacy of hepatitis B vaccination: knowledge among clinical medical students.

Authors:  B C Oates; A J Sidebottom; S R Maxwell
Journal:  BMJ       Date:  1993-07-31

4.  Efficacy of hepatitis B vaccine in the Gambian expanded programme on immunisation.

Authors:  M Fortuin; J Chotard; A D Jack; N P Maine; M Mendy; A J Hall; H M Inskip; M O George; H C Whittle
Journal:  Lancet       Date:  1993-05-01       Impact factor: 79.321

Review 5.  Prospects for control of hepatitis B virus infection: implications of childhood vaccination and long-term protection.

Authors:  C E Stevens; P T Toy; P E Taylor; T Lee; H Y Yip
Journal:  Pediatrics       Date:  1992-07       Impact factor: 7.124

6.  Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Eskimo population.

Authors:  R B Wainwright; B J McMahon; L R Bulkow; D B Hall; M A Fitzgerald; A P Harpster; S C Hadler; A P Lanier; W L Heyward
Journal:  JAMA       Date:  1989-04-28       Impact factor: 56.272

7.  Prospective evaluation of a monoclonal antibody in diagnosis of Pneumocystis carinii pneumonia.

Authors:  J A Kovacs; V Gill; J C Swan; F Ognibene; J Shelhamer; J E Parrillo; H Masur
Journal:  Lancet       Date:  1986-07-05       Impact factor: 79.321

8.  Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men.

Authors:  S C Hadler; D P Francis; J E Maynard; S E Thompson; F N Judson; D F Echenberg; D G Ostrow; P M O'Malley; K A Penley; N L Altman
Journal:  N Engl J Med       Date:  1986-07-24       Impact factor: 91.245
  8 in total
  11 in total

1.  Duration of hepatitis B antibody response in children immunised with hepatitis B and compulsory vaccines.

Authors:  S Li Volti; G Giammanco-Bilancia; G Giammanco; F Mollica
Journal:  Eur J Epidemiol       Date:  1995-04       Impact factor: 8.082

2.  A mathematical model predicting anti-hepatitis B virus surface antigen (HBs) decay after vaccination against hepatitis B.

Authors:  M C Honorati; A Palareti; P Dolzani; C A Busachi; R Rizzoli; A Facchini
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

3.  Hepatitis B vaccination ... and given booster injections.

Authors:  J A Lunn
Journal:  BMJ       Date:  1993-09-18

4.  Hepatitis B vaccination. Non-responders must be detected ...

Authors:  R S Tedder; M Zuckerman; N Brink
Journal:  BMJ       Date:  1993-09-18

5.  Hepatitis B vaccination schedules in genitourinary medicine clinics.

Authors:  D Asboe; P Rice; A de Ruiter; J S Bingham
Journal:  Genitourin Med       Date:  1996-06

6.  [Introduction of general hepatitis B vaccination in Switzerland].

Authors:  H Zimmermann; B Vaudaux; R Kammerlander
Journal:  Soz Praventivmed       Date:  1998

7.  Hepatitis B in children in Italy: incidence and risk factors: SEIEVA Collaborating Group. Sistema Epidemiologico Integrato dell'Epatite virale Acuta.

Authors:  R Corona; C Gandolfi; L Ferrigno; L Sagliocca; F Ciaralli; A Martelli; C Galanti; A Moiraghi; F Palumbo; F Novaco
Journal:  Eur J Epidemiol       Date:  1994-04       Impact factor: 8.082

8.  Hepatitis B vaccination: the cost effectiveness of alternative strategies in England and Wales.

Authors:  P Mangtani; A J Hall; C E Normand
Journal:  J Epidemiol Community Health       Date:  1995-06       Impact factor: 3.710

9.  Response to a booster dose 18 months after a low anti-HBs response (10-99 IU/l) to three doses of intradermally or intramuscularly administered recombinant hepatitis B vaccine.

Authors:  J Struve; B Aronsson; B Frenning; M Forsgren; O Weiland
Journal:  Infection       Date:  1995 Jan-Feb       Impact factor: 3.553

10.  Efficacy and effectiveness of infant vaccination against chronic hepatitis B in the Gambia Hepatitis Intervention Study (1986-90) and in the nationwide immunisation program.

Authors:  Thomas J Peto; Maimuma E Mendy; Yamundow Lowe; Emily L Webb; Hilton C Whittle; Andrew J Hall
Journal:  BMC Infect Dis       Date:  2014-01-07       Impact factor: 3.090
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.